BACKGROUND: Rucaparib is a potent, orally available, small-molecule inhibitor of poly ADP-ribose polymerase (PARP) 1 and 2. Ongoing clinical trials are assessing the efficacy of rucaparib alone or in combination with other cytotoxic drugs, mainly in breast and ovarian cancer patients with mutations in the breast cancer associated (BRCA) genes. PURPOSE: We aimed to establish whether the multidrug efflux transporters ABCG2 (BCRP) and ABCB1 (P-gp, MDR1) affect the oral availability and brain penetration of rucaparib in mice. RESULTS: In vitro, rucaparib was efficiently transported by both human ABCB1 and ABCG2, and very efficiently by mouse Abcg2. Transport could be inhibited by the small-molecule ABCB1 and ABCG2 inhibitors zosuquidar and Ko143, respectively. In vivo, oral availability (plasma AUC0-1 and AUC0-24) and brain levels of rucaparib at 1 and 24 h were increased by the absence of both Abcg2 and Abcb1a/1b after oral administration of rucaparib at 10 mg/kg. CONCLUSIONS: Our data show to our knowledge for the first time that oral availability and brain accumulation of a PARP inhibitor are markedly and additively restricted by Abcg2 and Abcb1a/1b. This may have clinical relevance for improvement of rucaparib therapy in PARP inhibitor-resistant tumors with ABCB1 and/or ABCG2 expression and in patients with brain (micro)metastases positioned behind a functional blood-brain barrier.
BACKGROUND:Rucaparib is a potent, orally available, small-molecule inhibitor of poly ADP-ribose polymerase (PARP) 1 and 2. Ongoing clinical trials are assessing the efficacy of rucaparib alone or in combination with other cytotoxic drugs, mainly in breast and ovarian cancerpatients with mutations in the breast cancer associated (BRCA) genes. PURPOSE: We aimed to establish whether the multidrug efflux transporters ABCG2 (BCRP) and ABCB1 (P-gp, MDR1) affect the oral availability and brain penetration of rucaparib in mice. RESULTS: In vitro, rucaparib was efficiently transported by both humanABCB1 and ABCG2, and very efficiently by mouseAbcg2. Transport could be inhibited by the small-molecule ABCB1 and ABCG2 inhibitors zosuquidar and Ko143, respectively. In vivo, oral availability (plasma AUC0-1 and AUC0-24) and brain levels of rucaparib at 1 and 24 h were increased by the absence of both Abcg2 and Abcb1a/1b after oral administration of rucaparib at 10 mg/kg. CONCLUSIONS: Our data show to our knowledge for the first time that oral availability and brain accumulation of a PARP inhibitor are markedly and additively restricted by Abcg2 and Abcb1a/1b. This may have clinical relevance for improvement of rucaparib therapy in PARP inhibitor-resistant tumors with ABCB1 and/or ABCG2 expression and in patients with brain (micro)metastases positioned behind a functional blood-brain barrier.
Authors: Sagar Agarwal; Ramola Sane; Jose L Gallardo; John R Ohlfest; William F Elmquist Journal: J Pharmacol Exp Ther Date: 2010-04-26 Impact factor: 4.030
Authors: Rolf W Sparidans; Selvi Durmus; Alfred H Schinkel; Jan H M Schellens; Jos H Beijnen Journal: J Pharm Biomed Anal Date: 2013-10-23 Impact factor: 3.935
Authors: Gergely Szakács; Jean-Philippe Annereau; Samir Lababidi; Uma Shankavaram; Angela Arciello; Kimberly J Bussey; William Reinhold; Yanping Guo; Gary D Kruh; Mark Reimers; John N Weinstein; Michael M Gottesman Journal: Cancer Cell Date: 2004-08 Impact factor: 31.743
Authors: Jurjen S Lagas; Robert A B van Waterschoot; Vicky A C J van Tilburg; Michel J Hillebrand; Nienke Lankheet; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel Journal: Clin Cancer Res Date: 2009-03-10 Impact factor: 12.531
Authors: Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman Journal: Nat Rev Drug Discov Date: 2006-03 Impact factor: 84.694
Authors: Jurjen S Lagas; Rolf W Sparidans; Robert A B van Waterschoot; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel Journal: Antimicrob Agents Chemother Date: 2008-01-14 Impact factor: 5.191
Authors: Andrea N Robinson; Bethelihem G Tebase; Sonia C Francone; Lyn M Huff; Hanna Kozlowski; Dominique Cossari; Jung-Min Lee; Dominic Esposito; Robert W Robey; Michael M Gottesman Journal: Drug Metab Dispos Date: 2019-05-02 Impact factor: 3.922
Authors: Karen E Parrish; Ling Cen; James Murray; David Calligaris; Sani Kizilbash; Rajendar K Mittapalli; Brett L Carlson; Mark A Schroeder; Julieann Sludden; Alan V Boddy; Nathalie Y R Agar; Nicola J Curtin; William F Elmquist; Jann N Sarkaria Journal: Mol Cancer Ther Date: 2015-10-05 Impact factor: 6.261